177559-01-2

Basic information

• Product Name: 3-(benzyloxy)-2-methylpyridine
• Synonyms: 3-(benzyloxy)-2-methylpyridine
• CAS NO: 177559-01-2
• Molecular Weight: 199.252
• Mol File: 177559-01-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-(benzyloxy)-2-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(benzyloxy)-2-methylpyridine(177559-01-2)
• EPA Substance Registry System: 3-(benzyloxy)-2-methylpyridine(177559-01-2)

Safety Data

• Hazardous Substances Data: 177559-01-2(Hazardous Substances Data)

Upstream product

• 1121-25-1 2-methyl-3-pyridinol 
• 100-39-0 benzyl bromide 

Downstream Products

• 324519-77-9 C₂₀H₂₁NO₃ 
• 6059-29-6 3-Benzyloxy-2-(hydroxymethyl)pyridine 
• 1048660-74-7 N-(4-methylpentan-2-one)-3-(benzyloxy)-2-methylpyridinate bromide 
• 177557-54-9 2-(8-(carbomethoxymethyloxy)-3-(3,5-di-t-butylbenzyl)-2-ethylindolizin-1-yl)glyoxylamide 
• 177557-32-3 2-(8-benzyloxy-3-(3,5-di-t-butylbenzyl-2-ethylindolizin-1-yl))glyoxylamide 
• 1027326-10-8 [8-Benzyloxy-3-(3,5-di-tert-butyl-benzyl)-2-ethyl-indolizin-1-yl]-oxo-acetyl chloride 
• 177557-56-1 2-(3-o-benzylbenzyl-8-(carbomethoxymethyloxy)-2-ethylindolizin-1-yl)glyoxylamide 
• 177557-36-7 2-(8-benzyloxy-2-ethyl-3-((3-thiophen-2-yl)thiophen-2-ylmethyl)indolizin-1-yl)glyoxylamide 
• 177557-60-7 2-(2-Ethyl-8-(carbomethoxymethyloxy)-3-(o-nitrobenzyl)indolizine-1-yl)glyoxylamide 
• 177557-34-5 2-(8-Benzyloxy-3-(o-benzylbenzyl)-2-ethylindolizin-1-yl)glyoxylamide 
• 1026809-54-0 [3-(2-Benzyl-benzyl)-8-benzyloxy-2-ethyl-indolizin-1-yl]-oxo-acetyl chloride 
• 177557-47-0 2-(2-ethyl-8-(carbomethoxymethyloxy)-3-(o-phenylbenzyl)indolizine-1-yl)glyoxylamide 
• 177557-39-0 2-[8-Benzyloxy-2-ethyl-3-(4-pentyl-cyclohexylmethyl)-indolizin-1-yl]-2-oxo-acetamide 
• 177557-88-9 2-(3-(Biphenyl-2-ylmethyl)-8-(carbomethoxymethyloxy)-2-methylindolizin-1-yl)glyoxylamide 

Relevant articles and documents

Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation

Gd-based MRI contrast agents (GBCAs) have come under intense regulatory scrutiny due to concerns of Gd retention and delayed toxicity. Three GBCAs comprising acyclic Gd chelates, the class of GBCA most prone to Gd release, are no longer marketed in Europe

Acid-catalyzed rearrangement of 1-benzyl-2-methyl-3-piperidone to 1-benzyl-2-acetylpyrrolidine

We report that 1-benzyl-2-methyl-3-piperidone, conveniently prepared from 3-hydroxy-2-methylpyridine, undergoes rearrangement to 1-benzyl-2-acetylpyrrolidine in aqueous 6 N HCl at reflux. Studies showing that the 2,2-dimethyl analog is inert under the same conditions support a mechanism of reversible tautomeric equilibria via ring-opened intermediates, one of which was independently synthesized and shown to be a kinetically competent intermediate to product.

Indolizine SPLA2inhibitors

A class of novel indolizine-1-functional compounds and indolizine-3-functional compounds is disclosed together with the use of such indolizine compounds for inhibiting sPLA2mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are indolizine-1-acetamides, indolizine-1-acetic acid hydrazides, indolizine-1-glyoxylamides, indolizine-3-acetamides, indolizine-3-acetic acid hydraxides, and indolizine-3-glyoxylasides.